-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EyHVNiXxxrf08wzX0cgw2Xf2yNqPuKmYm6FmeGoBCc41MDZAIuuPnjk2j/KcXiO+ 20+GyjaAm57caN016ZUhjA== 0000950144-05-012773.txt : 20051214 0000950144-05-012773.hdr.sgml : 20051214 20051214172338 ACCESSION NUMBER: 0000950144-05-012773 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051209 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20051214 DATE AS OF CHANGE: 20051214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RENAL CARE GROUP INC CENTRAL INDEX KEY: 0000920052 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 621622383 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16733 FILM NUMBER: 051264681 BUSINESS ADDRESS: STREET 1: 2100 WEST END AVENUE STREET 2: SUITE 800 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153455500 8-K 1 g98840e8vk.htm RENAL CARE GROUP, INC. RENAL CARE GROUP, INC.
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 9, 2005
Renal Care Group, Inc.
 
(Exact name of Registrant as specified in its charter)
         
Delaware
(State or Other Jurisdiction of
Incorporation) 		  0-27640
(Commission
File Number) 		  62-1622383
(I.R.S. Employer
Identification No.)
     
2525 West End Avenue, Suite 600, Nashville, Tennessee
(Address of Principal Executive Offices) 		  37203
(Zip Code)
(615) 345-5500
(Registrant’s telephone number, including area code)
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 1.01 Entry into a Material Definitive Agreement.
Item 9.01 Financial Statements and Exhibits.
SIGNATURE

Table of Contents

Item 1.01 Entry into a Material Definitive Agreement.
     Renal Care Group, Inc. (“RCG”) entered into a Dialysis Organization Agreement with Amgen USA, Inc. (“Amgen”) on December 9, 2005 (the “Agreement”). The Agreement sets forth the terms and conditions under which RCG will purchase Epoetin alfa (“EPOGEN”) and Darbepoetin alfa (individually, “Aranesp” and collectively with EPOGEN, the “Products”) from Amgen. The term of the Agreement commences January 1, 2006 and ends December 31, 2007.
     The Agreement provides for discount pricing for Aranesp and EPOGEN purchased by RCG and its affiliates. The parties have also provided for specific rebates and incentives with respect to the Products, subject to various qualification requirements for which RCG will be evaluated during the term of the Agreement. These qualification requirements are based on a variety of factors including patient outcomes targets, process improvement targets, data submission targets, volume growth of purchases of the Products by RCG and its affiliates and incentives calculated using a combination of these factors.
Item 9.01 Financial Statements and Exhibits.
     None.

-2-

Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  RENAL CARE GROUP, INC.
 		  
  By:   /s/David M. Dill    
    David M. Dill   
    Executive Vice President and Chief Financial Officer   
 
         
     
Dated: December 14, 2005     
     
     
 

-3-

-----END PRIVACY-ENHANCED MESSAGE-----